Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

Relief Therapeutics Holding SA / Key word(s): Miscellaneous Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission 27-Dec-2022 / 07:15 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer is solely responsible for the content of this announcement. Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission

GENEVA, Dec. 27, 2022 – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relief), announced today that it has filed Amendment No. 2 to its Registration Statement on Form F-1 under the Securities Act of 1933 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed offering of its ordinary shares in the form of American Depositary Shares (ADSs). The preliminary prospectus provides for the possible sale of 833,333,200 ordinary shares in the form of ADSs (4,166,666 ADSs) in the United States and warrants to purchase 625,000,000 ordinary shares in the form ADSs (3,125,000 ADSs). In addition, the preliminary prospectus sets forth that Relief will grant the underwriters an option to purchase up to an additional 125,000,000 ordinary shares in the form of ADSs (625,000 ADSs) and additional warrants to purchase up to 93,750,000 additional shares in the form of ADSs (468,750 ADSs). The number of ADSs to be offered and the price range remain subject to change, and there can be no assurance that the offering contemplated by the registration statement will be completed. Relief will report the final terms of the contemplated offering once fixed in a future amendment to its registration statement. The offering, if made, will only be made by means of an effective prospectus. Further information is available in the Amendment No. 2 here.

ABOUT RELIEF

Relief is a Swiss, commercial-stage, biopharmaceutical company focused on identification, development and commercialization of novel, patent protected products intended for the treatment of rare and ultra-rare diseases including metabolic disorders, pulmonary diseases, and connective tissue disorders. Relief’s diversified pipeline consists of assets that have the potential to effectively address significant unmet medical needs, including PKU GOLIKE, engineered with the proprietary Physiomimic technology, which is the first prolonged-release amino acid product commercialized for the dietary management of phenylketonuria (PKU). Relief has a collaboration and license agreement with Acer Therapeutics for the worldwide development and commercialization of ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and maple syrup urine disease (MSUD). Relief also continues to develop aviptadil for several rare pulmonary indications. Further, Relief is in clinical development for APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid intended for the treatment of epidermolysis bullosa (EB), a group of rare, genetic, life-threatening connective tissue disorders; APR-TD011 has been granted Orphan Drug Designation by the U.S. FDA. Finally, Relief is commercializing several legacy products via licensing and distribution partners.